UI Hospitals and Clinics

Studies | Researchers

Clinical Research

Showing newest first. Show oldest first. Or order by title

  1. A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
    David Bender
  2. Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymp…
    Ayman El-Sheikh
  3. Transfusion of Prematures (TOP) Trial
    Edward F. Bell
  4. A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND #74019, NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
    David Bender
  5. A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexat…
    Ayman El-Sheikh
  6. Cognitive and Psychiatric Functioning in Adults with Carcinoid Tumors
    Megan Smith
  7. Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer
    Daniel Vaena
  8. Randomized Phase II Study Comparing the MET inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
    Mohammed Milhem
  9. Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc P(1)
    Brian Link
  10. GOG 3001/ Amgen TRINOVA-3 - A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III…
    David Bender
  11. Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
    Ayman El-Sheikh
  12. A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) vs. Observation for Uterus-limited, High Grade Uterine Leiomyosarcoma
    David Bender
  13. A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Rel…
    Brian Link
  14. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects…
    Brian Link
  15. A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresecta…
    Mohammed Milhem
  16. Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Pa(1)
    Daniel Vaena
  17. Randomized, double-blind phase III study of Pazopanib vs Placebo in subjects with metastatic renal cell carcinoma who have no evidence of disease following metastatectomy
    Daniel Vaena
  18. A Phase 2 Study of MLN8237 in Advanced / Metastatic Sarcoma(1)
    Mohammed Milhem
  19. Biobehavioral-Cytokine Interactions in Ovarian Cancer
    Susan Lutgendorf
  20. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Tabalumab in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma
    Guido Tricot

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.